As of November 14, 2026, Repare Therapeutics Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on January 28, 2026 (Form 8-K, January 28, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Repare Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Repare Therapeutics Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-01-28. Every row below is cited to the filing it comes from, and this page adds each new change as Repare Therapeutics Inc. files it.
Layoffs on record: 2 filings or notices, latest 2025-02-25 (layoff filings and notices).
Also on the record for Repare Therapeutics Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 14, 2026 | Stake report, Schedule 13G/A, by Blue Owl Capital Holdings LP | — | 5%+ stakes | Source |
| January 30, 2026 | Stake report, Schedule 13D/A, by BIOTECHNOLOGY VALUE FUND L P | — | 5%+ stakes | Source |
| January 27, 2026 | Stake report, Schedule 13G, by Shay Capital LLC | 6.7% of the class | 5%+ stakes | Source |
| November 24, 2025 | Stake report, Schedule 13D/A, by BIOTECHNOLOGY VALUE FUND L P | 24% of the class | 5%+ stakes | Source |
| November 21, 2025 | Stake report, Schedule 13D/A, by Versant Venture Capital V, L.P. | 0.2% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Repare Therapeutics Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Repare Therapeutics Inc. and the records around it.
Repare Therapeutics Inc. elsewhere on the record
- 5%+ stake filings May 2026
- Layoff notices Feb 2025
Companies that share a holder
- Shay Capital LLC also filed stake reports on 7 other companies: Xponential Fitness, Inc. (Jun 2026), DUOS TECHNOLOGIES GROUP, INC. (May 2026), A2Z CUST2MATE SOLUTIONS CORP. (Apr 2026)
- Blue Owl Capital Holdings LP also filed stake reports on 11 other companies: ImageneBio, Inc. (Nov 2026), Latigo Biotherapeutics, Inc. (Nov 2026), Context Therapeutics Inc. (Aug 2026)
- BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Olema Pharmaceuticals, Inc. (Oct 2026), Foghorn Therapeutics Inc. (Oct 2026)
Watch Repare Therapeutics Inc.
Get an email when Repare Therapeutics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Repare Therapeutics Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Repare Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Repare Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-01-28 | Reported | not named in the filing | 8-K, 2026-01-28 |
New leaders reset buying decisions — get the Full Report on Repare Therapeutics Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Repare Therapeutics Inc., with the record behind each one.
Find candidates like senior executive at Repare Therapeutics Inc.Every change, in the filing's words
Reported
Departure of Directors; Election of Directors; Appointment of Certain Officers.
- In connection with the Transaction and pursuant to the terms of the Agreement, at the effective time of the Transaction (the "Effective Time"), each of the directors of the Company resigned from the board of directors of the Company.
- Pursuant to the terms of the Agreement, at the Effective Time, the sole director of Purchaser became the sole director of the surviving corporation following the completion of the Transaction.
- The sole director of Purchaser immediately prior to the Effective Time was Jon Adkins.
- The sole officer of Purchaser immediately prior to the Effective Time was Jon Adkins, serving as President, Treasurer and Secretary.
- Following the Closing, Jon Adkins is expected to become the sole officer of the Company.
Tools for this story
Each opens in a new tab, filled in for Repare Therapeutics Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
